Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10556953 | 0.91 | HTR2C (0.36) | HTR2CHTR2B | |
| SCHEMBL29207081 | 0.89 | HTR2C (0.40) | HTR2CHTR2BMEN1KMT2ACYP2D6 | |
| SCHEMBL20111596 | 0.84 | FASN (0.33) | FASN | |
| SCHEMBL17528168 | 0.82 | FASN (0.36) | FASNCYP2C9MEN1KMT2ACYP2D6 | |
| SCHEMBL17365890 | 0.81 | HTR2C (0.44) | HTR2CHTR2BCYP2D6TAAR1 | |
| SCHEMBL13263190 | 0.81 | HDAC3 (0.36) | FASN | |
| SCHEMBL9016061 | 0.80 | FASN (0.37) | FASN | |
| SCHEMBL12024585 | 0.80 | FASN (0.33) | FASNCYP2C9MEN1KMT2ACYP2D6 | |
| SCHEMBL19818330 | 0.80 | SLC6A2 (0.37) | FASN | |
| SCHEMBL12024510 | 0.79 | CYP2C9 (0.36) | FASNOPRL1CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2987790-B1 | LIQUID CRYSTAL COMPOUND HAVING XANTHENE SKELETON AND EXHIBITING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORP (JP) | 2019-08-28 | — | — | EP | disclosed |
| US-9879182-B2 | Liquid crystal compound having xanthene skeleton and exhibiting negative dielectric anisotropy, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-01-30 | — | — | US | disclosed |
| US-9879182-B2 | Liquid crystal compound having xanthene skeleton and exhibiting negative dielectric anisotropy, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-01-30 | — | — | US | disclosed |
| US-20160068754-A1 | LIQUID CRYSTAL COMPOUND HAVING XANTHENE SKELETON AND EXHIBITING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) | 2016-03-10 | — | — | US | disclosed |
| US-20160068754-A1 | LIQUID CRYSTAL COMPOUND HAVING XANTHENE SKELETON AND EXHIBITING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) | 2016-03-10 | — | — | US | disclosed |
| EP-2987790-A1 | LIQUID CRYSTAL COMPOUND HAVING XANTHENE SKELETON AND EXHIBITING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2016-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068754-A1 | LIQUID CRYSTAL COMPOUND HAVING XANTHENE SKELETON AND EXHIBITING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | OCIAD2, CALCOCO2, CCDC22 | HTR2C 1034/4885HTR2B 2847/4885FASN 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.